Results 211 to 220 of about 681,060 (251)

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin.

i Medicina
BACKGROUND Psilocybin-assisted psychotherapy (PAP) has been associated with antidepressant effects. Trials to date have typically excluded participants with complex presentations.
J. Rosenblat, Shakila Meshkat, Zoe Doyle, Erica S. Kaczmarek, Ryan M. Brudner, Kevin Kratiuk, Rodrigo B. Mansur, Christian Schulz-Quach, Rickinder Sethi, Amanda Abate, Shaun Ali, Jordan Bawks, Marc G. Blainey, Elisa Brietzke, Victoria Cronin, Jessica Danilewitz, S. Dhawan, A. Di Fonzo, Melissa Di Fonzo, Pawel Drzadzewski, W. Dunlop, Hajnalka Fiszter, Fabiano A. Gomes, Smrita Grewal, Marisa Leon-Carlyle, M. Mccallum, Niki Mofidi, Hilary Offman, Jeremy Riva-Cambrin, Joel Schmidt, Mark Smolkin, J. M. Quinn, Andrea Zumrova, M. Marlborough, R. McIntyre   +34 more
semanticscholar   +1 more source

Treatment resistant depression in elderly

2023
Treatment refractory depression (TRD) in the elderly is a common psychiatric disorder with high comorbidity and mortality. Older adults with TRD often have complicated comorbidities and several predisposing risk factors, which may lead to neuropsychiatric dysfunction and poor response to treatment.
Sheng-Chiang, Wang, Jennifer S, Yokoyama, Nian-Sheng, Tzeng, Chia-Fen, Tsai, Mu-N, Liu   +4 more
openaire   +2 more sources

Esketamine for Treatment-Resistant Depression

JAMA Psychiatry
To the Editor Janik et al reported a positive trial of esketamine monotherapy for treatment-resistant depression. However, the lead-in design and functional unblinding could have biased treatment estimates. The 4-week double-blind phase was preceded by a lead-in phase of up to 7 weeks, during which time antidepressant medication was discontinued ...
Cristea I. A., Plöderl M., Naudet F.
openaire   +4 more sources

Targeting Treatment-Resistant Depression

Journal of Pharmacy Practice, 2011
Only 50% of depressed patients achieve remission of symptoms after 2 trials of antidepressants. Therefore one half of patients are considered treatment resistant. Studies have shown that with each failed antidepressant, chances of remission continue to decline.
Monica, Mathys, Brian G, Mitchell
openaire   +2 more sources

Treatment-resistant depression.

The Journal of clinical psychiatry, 2006
info:eu-repo/semantics ...
Souery, Daniel, Papakostas, George I.George, Trivedi, Madhukar   +2 more
openaire   +2 more sources

Treatment-resistant depression: molecular mechanisms and management

Molecular Biomedicine
Due to the heterogeneous nature of depression, the underlying etiological mechanisms greatly differ among individuals, and there are no known subtype-specific biomarkers to serve as precise targets for therapeutic efficacy. The extensive research efforts
Mayanja M. Kajumba, Angelina Kakooza-Mwesige, N. Nakasujja, Deborah C. Koltai, T. Canli   +4 more
semanticscholar   +1 more source

Vagus nerve stimulation: An update on a novel treatment for treatment-resistant depression.

Journal of Neurological Sciences, 2022
In this review, we provide an overview of essential clinical trials examining the effect of vagal nerve stimulation (VNS) in treatment-resistant depression (TRD), the applicable neuroanatomy of the vagus nerve, and the proposed mechanism of action (MOA ...
Lojine Y. Kamel, Willa Xiong, Britt M. Gott, Arun Kumar, C. Conway   +4 more
semanticscholar   +1 more source

Esketamine for treatment-resistant depression

Drug and Therapeutics Bulletin, 2020
Generic name: Esketamine hydrochloride Brand name: Spravato Formulation: 28mg in 0.2ml nasal spray solution Market Authorisation holder: Janssen-Cilag International NV Indication: Treatment resistant
openaire   +2 more sources

A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019.

Journal of Affective Disorders, 2020
BACKGROUND Sub-anaesthetic administration of ketamine is an emerging practice in patients presenting treatment resistant depression (TRD), however several outstanding questions have yet to be answered.
W. Marcantoni, Bertine Sandra Akoumba, M. Wassef, Julie Mayrand, H. Lai, S. Richard-Devantoy, S. Beauchamp   +6 more
semanticscholar   +1 more source

Migraine and treatment-resistant depression

2023
Migraine and major depressive disorders (MDD) or treatment resistant depression (TRD) represent a significant global burden and are often comorbid, further complicating diagnosis and treatment. Epidemiological studies have demonstrated a bidirectional relationship between migraine and MDD/TRD, with patients suffering from one disorder exhibiting a ...
openaire   +2 more sources